about
Rare but authentic Philadelphia-positive acute myeloblastic leukemia: two case reports and a literature review of characteristics, treatment and outcomeRituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles.Hematogones: an overview.An unusual Sézary syndrome with concomitant pulmonary localization: aggressiveness of folliculotropic form.Leptomeningeal involvement in CLL.Dynamics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia.Blood transfusion in hematologic intensive care unit.The prognostic value of hematogones in patients with acute myeloid leukemia.Transfusion strategy in hematological intensive care unit: study protocol for a randomized controlled trial.Severe chronic primary neutropenia in adults: report on a series of 108 patients.Full response of a localized renal tumour after reduced-intensity conditioned hematopoietic stem cell transplantationUnusual Extramedullary Plasmacytoma: A Rare but Possible Cause of Lymphadenopathy in Chronic Lymphocytic Leukemia.Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia.5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases.Hematogones: a new prognostic factor for acute myeloblastic leukemia.ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia.[Dasatinib-related pneumonia? An example of pharmacovigilance survey].Midostaurin in Advanced Systemic MastocytosisFractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French associationIgM multiple myeloma: more on a rare and heterogeneous diseaseTreatment of adult ALL with central nervous system involvement at diagnosis using autologous and allogeneic transplantation: a study from the Société Française de Greffe de Moelle et de Thérapie CellulaireSemi-ambulatory autologous peripheral blood SCT in 79 patients with multiple myelomaAllogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell TherapyThe level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemiaPredictive factors for a single successful cytapheresis session during the first mobilisationFeasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: a single-center experience[Management of graft failure and erythroblastopenia in patients undergoing allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Be ever cautious until the truth is proven
P50
Q27026460-6C037709-C4D8-4548-9359-123954E40CECQ33431198-CCBC4B2A-BA1D-4D59-91FF-FB066C2D3CCBQ38128004-C52D7CBC-22A7-41F7-B849-17748EEAA1FBQ38201791-5C56B06F-6067-48D7-B040-BE405E3733F8Q38608387-5114A4C9-EB57-4609-A1C4-75E3C2AF2358Q40315690-FBE9A0F1-BB30-4CAB-A8FA-4E7F6D8E82DDQ40468838-CE73276E-71A0-4BE3-B622-9CE6BE7638E6Q40876342-DAF3F94D-1EA1-43E4-9CC1-25F0FF6A519BQ40900632-24A000B2-F2A6-43E6-8749-74FA62932FD2Q41059821-F0041783-79AD-4565-824D-8AA668FB3BE0Q41902243-EA56250A-E614-4954-92B6-5CA06A16C4D1Q42361388-5519794C-5DEC-47B4-B3BC-BE4B202BDEB1Q44462005-C94327C5-F5A2-4A86-A3BE-AA2BFE526443Q51039721-C34B7D4B-2788-4A10-9963-8D2C680D9D1EQ51748595-C8FA1958-6ABE-4864-A910-64467FA40A33Q52884713-B00C738C-22D8-4F85-BDC5-02B228066DADQ54337257-CB0F33F0-1F6E-4A68-950B-9CF09105D223Q54707187-8645EDAD-A05E-45A7-99E9-F8F2DA7D852AQ55068472-995D2D0C-72C8-492E-816D-1D8F20B552E6Q56977697-26AD78D2-198B-4888-A210-D0427BA7F061Q58415977-061BEC86-DE3F-4F9C-9066-237BA53BD5B3Q84240573-9C376CB4-793D-47DF-A162-7E4A9ED36C14Q85486442-5B2F5D6C-EAD1-44D5-8DE7-4F20B2E8828EQ85962899-099FDC10-502F-4644-AC76-4EB3E8147083Q86135886-E103CA37-0915-45E2-807E-18703F8C874BQ87397188-789CC317-ADE0-4AFD-B171-4F38A14C6059Q87466534-69A4DFEF-E9AA-4E35-BBF4-94F9FC168FF8Q87491373-3F352E92-6C0E-4839-B55A-E37BE3AAE7D8Q88680891-D63DD24E-A11F-4929-899C-F6148F4B2AFDQ91137937-259CA236-8B06-4E79-8ACC-E4AA55D00367
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sylvain Chantepie
@ast
Sylvain Chantepie
@en
Sylvain Chantepie
@es
Sylvain Chantepie
@nl
Sylvain Chantepie
@sl
type
label
Sylvain Chantepie
@ast
Sylvain Chantepie
@en
Sylvain Chantepie
@es
Sylvain Chantepie
@nl
Sylvain Chantepie
@sl
prefLabel
Sylvain Chantepie
@ast
Sylvain Chantepie
@en
Sylvain Chantepie
@es
Sylvain Chantepie
@nl
Sylvain Chantepie
@sl
P106
P21
P31
P496
0000-0003-0457-2252